Abstract
Parkinson’s disease (PD) is associated with higher risk of cognitive impairment that may lead to memory loss, confusion, and decreased attention span. In this study, we have investigated the effect of GW0742, a PPAR-β/δ agonist in rat model of cognitive impairment associated with PD. Bilateral intranigral administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) (100 µg/1 µl/side) produced significant cognitive dysfunctions. PPAR-β/δ agonist GW0742 at a dose of 30 and 100 µg/kg showed significant improvement in cognitive impairments caused by MPTP in rat model of PD as evident from passive avoidance and Morris water maze test. MPTP-induced massive oxidative damage and DNA fragmentation was ameliorated by GW0742 treatment as observed after MDA and GSH estimation and TUNEL assay. Tyrosine hydroxylase positive neurons were decreased by 25% of normal control in MPTP group and GW0742 treatment restored tyrosine hydroxylase levels showing neuroprotective nature. Further, we performed physiologically based pharmacokinetic (PBPK) modeling study using GastroPlus to characterize the kinetics of GW0742 in the brain. The predicted amounts of GW0742 in brain suggest that it has the ability to cross the blood brain barrier. This study implicates the involvement of PPAR-β/δ in PD induced cognitive impairment.
Keywords: GastroPlus, GW0742, MPTP, parkinson’s disease, PBPK modeling, PPAR beta.
Current Neurovascular Research
Title:A PPAR-β/δ Agonist is Neuroprotective and Decreases Cognitive Impairment in a Rodent Model of Parkinson’s Disease
Volume: 11 Issue: 2
Author(s): Nihar R. Das, Rahul P. Gangwal, Mangesh V. Damre, Abhay T. Sangamwar and Shyam S. Sharma
Affiliation:
Keywords: GastroPlus, GW0742, MPTP, parkinson’s disease, PBPK modeling, PPAR beta.
Abstract: Parkinson’s disease (PD) is associated with higher risk of cognitive impairment that may lead to memory loss, confusion, and decreased attention span. In this study, we have investigated the effect of GW0742, a PPAR-β/δ agonist in rat model of cognitive impairment associated with PD. Bilateral intranigral administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) (100 µg/1 µl/side) produced significant cognitive dysfunctions. PPAR-β/δ agonist GW0742 at a dose of 30 and 100 µg/kg showed significant improvement in cognitive impairments caused by MPTP in rat model of PD as evident from passive avoidance and Morris water maze test. MPTP-induced massive oxidative damage and DNA fragmentation was ameliorated by GW0742 treatment as observed after MDA and GSH estimation and TUNEL assay. Tyrosine hydroxylase positive neurons were decreased by 25% of normal control in MPTP group and GW0742 treatment restored tyrosine hydroxylase levels showing neuroprotective nature. Further, we performed physiologically based pharmacokinetic (PBPK) modeling study using GastroPlus to characterize the kinetics of GW0742 in the brain. The predicted amounts of GW0742 in brain suggest that it has the ability to cross the blood brain barrier. This study implicates the involvement of PPAR-β/δ in PD induced cognitive impairment.
Export Options
About this article
Cite this article as:
Das R. Nihar, Gangwal P. Rahul, Damre V. Mangesh, Sangamwar T. Abhay and Sharma S. Shyam, A PPAR-β/δ Agonist is Neuroprotective and Decreases Cognitive Impairment in a Rodent Model of Parkinson’s Disease, Current Neurovascular Research 2014; 11 (2) . https://dx.doi.org/10.2174/1567202611666140318114037
DOI https://dx.doi.org/10.2174/1567202611666140318114037 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
COX-Inhibiting Nitric Oxide Donors (CINODs): Potential Benefits on Cardiovascular and Renal Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy Contrast Functions of αA- and αB-Crystallins in Cancer Development
Current Molecular Medicine Nesfatin-1 and the Cardiovascular System: Central and Pheripheral Actions and Cardioprotection
Current Drug Targets NMNAT Expression and its Relation to NAD Metabolism
Current Medicinal Chemistry Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Antioxidative Effects of Rhodiola Genus: Phytochemistry and Pharmacological Mechanisms against the Diseases
Current Topics in Medicinal Chemistry The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression
Current Drug Targets Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology Alzheimer’s Disease and Antioxidant Therapy: How Long How Far?
Current Medicinal Chemistry Agonism of Histaminergic-H<sub>1</sub> Receptors in Ischemic Postconditioning During Cerebral Ischemia-Reperfusion Injury is Protective
Current Neurovascular Research TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets Application of Hydrogen in Ophthalmology
Current Pharmaceutical Design Folic Acid Can Contribute to Memory Deficit and Na+, K+- ATPase Failure in the Hippocampus of Adolescent Rats Submitted to Hypoxia- Ischemia
CNS & Neurological Disorders - Drug Targets Microglia-Targeted Pharmacotherapy in Retinal Neurodegenerative Diseases
Current Drug Targets Novel Therapeutic Approaches in Limiting Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Targeting Extracellular Matrix Proteolysis for Hemorrhagic Complications of tPA Stroke Therapy
CNS & Neurological Disorders - Drug Targets A Facile “Click Chemistry” Approach to Novel Flavonol Glycoconjugates and Their Cytotoxic Activity
Letters in Organic Chemistry